377 related articles for article (PubMed ID: 23391537)
1. Alternative pathway dysfunction in kidney disease: a case report and review of dense deposit disease and C3 glomerulopathy.
Hawfield A; Iskandar SS; Smith RJ
Am J Kidney Dis; 2013 May; 61(5):828-31. PubMed ID: 23391537
[TBL] [Abstract][Full Text] [Related]
2. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies.
Servais A; Noël LH; Roumenina LT; Le Quintrec M; Ngo S; Dragon-Durey MA; Macher MA; Zuber J; Karras A; Provot F; Moulin B; Grünfeld JP; Niaudet P; Lesavre P; Frémeaux-Bacchi V
Kidney Int; 2012 Aug; 82(4):454-64. PubMed ID: 22456601
[TBL] [Abstract][Full Text] [Related]
3. Severe active C3 glomerulonephritis triggered by immune complexes and inactivated after eculizumab therapy.
Kersnik Levart T; Ferluga D; Vizjak A; Mraz J; Kojc N
Diagn Pathol; 2016 Oct; 11(1):94. PubMed ID: 27717365
[TBL] [Abstract][Full Text] [Related]
4. Membranoproliferative glomerulonephritis with isolated C3 deposits: case report and literature review.
Darouich S; Goucha R; Jaafoura MH; Zekri S; Kheder A; Ben Maiz H
Ultrastruct Pathol; 2011 Feb; 35(1):42-6. PubMed ID: 21265634
[TBL] [Abstract][Full Text] [Related]
5. Pathology of renal diseases associated with dysfunction of the alternative pathway of complement: C3 glomerulopathy and atypical hemolytic uremic syndrome (aHUS).
Sethi S; Fervenza FC
Semin Thromb Hemost; 2014 Jun; 40(4):416-21. PubMed ID: 24799306
[TBL] [Abstract][Full Text] [Related]
6. C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy.
Bomback AS; Santoriello D; Avasare RS; Regunathan-Shenk R; Canetta PA; Ahn W; Radhakrishnan J; Marasa M; Rosenstiel PE; Herlitz LC; Markowitz GS; D'Agati VD; Appel GB
Kidney Int; 2018 Apr; 93(4):977-985. PubMed ID: 29310824
[TBL] [Abstract][Full Text] [Related]
7. C3 glomerulonephritis with a severe crescentic phenotype.
Ravindran A; Fervenza FC; Smith RJH; Sethi S
Pediatr Nephrol; 2017 Sep; 32(9):1625-1633. PubMed ID: 28593446
[TBL] [Abstract][Full Text] [Related]
8. C3 glomerulopathy and current dilemmas.
Ito N; Ohashi R; Nagata M
Clin Exp Nephrol; 2017 Aug; 21(4):541-551. PubMed ID: 27878657
[TBL] [Abstract][Full Text] [Related]
9. Dense deposit disease in a child with febrile sore throat.
Conti G; De Vivo D; Vitale A; Fede C; Santoro D
Saudi J Kidney Dis Transpl; 2017; 28(4):925-928. PubMed ID: 28748900
[TBL] [Abstract][Full Text] [Related]
10. Toward a working definition of C3 glomerulopathy by immunofluorescence.
Hou J; Markowitz GS; Bomback AS; Appel GB; Herlitz LC; Barry Stokes M; D'Agati VD
Kidney Int; 2014 Feb; 85(2):450-6. PubMed ID: 24067430
[TBL] [Abstract][Full Text] [Related]
11. Characterization of C3 in C3 glomerulopathy.
Sethi S; Vrana JA; Fervenza FC; Theis JD; Sethi A; Kurtin PJ; Zhang Y; Smith RJH
Nephrol Dial Transplant; 2017 Mar; 32(3):459-465. PubMed ID: 27507892
[TBL] [Abstract][Full Text] [Related]
12. Clinico-pathologic spectrum of C3 glomerulopathy-an Indian experience.
Viswanathan GK; Nada R; Kumar A; Ramachandran R; Rayat CS; Jha V; Sakhuja V; Joshi K
Diagn Pathol; 2015 Mar; 10():6. PubMed ID: 25889427
[TBL] [Abstract][Full Text] [Related]
13. C3 glomerulopathy: what's in a name?
D'Agati VD; Bomback AS
Kidney Int; 2012 Aug; 82(4):379-81. PubMed ID: 22846813
[TBL] [Abstract][Full Text] [Related]
14. Treatment of C3 glomerulopathy with complement blockers.
Vivarelli M; Emma F
Semin Thromb Hemost; 2014 Jun; 40(4):472-7. PubMed ID: 24799307
[TBL] [Abstract][Full Text] [Related]
15. Dense deposit disease and C3 glomerulopathy.
Barbour TD; Pickering MC; Terence Cook H
Semin Nephrol; 2013 Nov; 33(6):493-507. PubMed ID: 24161036
[TBL] [Abstract][Full Text] [Related]
16. C3 Glomerulopathy: Pathogenesis and Treatment.
Ahmad SB; Bomback AS
Adv Chronic Kidney Dis; 2020 Mar; 27(2):104-110. PubMed ID: 32553242
[TBL] [Abstract][Full Text] [Related]
17. Extensive complement activation in hereditary porcine membranoproliferative glomerulonephritis type II (porcine dense deposit disease).
Jansen JH; Høgåsen K; Mollnes TE
Am J Pathol; 1993 Nov; 143(5):1356-65. PubMed ID: 8238252
[TBL] [Abstract][Full Text] [Related]
18. Membranoproliferative glomerulonephritis: pathogenetic heterogeneity and proposal for a new classification.
Sethi S; Fervenza FC
Semin Nephrol; 2011 Jul; 31(4):341-8. PubMed ID: 21839367
[TBL] [Abstract][Full Text] [Related]
19. Pathogenesis of the C3 glomerulopathies and reclassification of MPGN.
Bomback AS; Appel GB
Nat Rev Nephrol; 2012 Nov; 8(11):634-42. PubMed ID: 23026947
[TBL] [Abstract][Full Text] [Related]
20. Membranoprolferative glomerulonephritis - mechanisms and treatment.
Appel GB
Contrib Nephrol; 2013; 181():163-74. PubMed ID: 23689578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
